Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591244 | 0.80 | NPC1 (0.43) | CYP11B1CYP11B2GRM2SCDNPC1 | |
| SCHEMBL4590539 | 0.80 | RAB9A (0.46) | CYP11B1CYP11B2NPC1RAB9ANFKB1 | |
| SCHEMBL4590809 | 0.76 | CYP11B1 (0.54) | CYP11B1CYP11B2GRM2IL4I1NPC1 | |
| SCHEMBL4591034 | 0.76 | CYP11B1 (0.51) | CYP11B1CYP11B2GRM2IL4I1NPC1 | |
| SCHEMBL22454021 | 0.73 | CYP11B1 (0.53) | CYP11B1CYP11B2GRM2IL4I1NPC1 | |
| SCHEMBL27726713 | 0.73 | CYP11B1 (0.53) | CYP11B1CYP11B2GRM2IL4I1NPC1 | |
| SCHEMBL25214525 | 0.73 | DAO (0.43) | — | |
| SCHEMBL30469149 | 0.73 | DAO (0.43) | — | |
| SCHEMBL15060601 | 0.72 | CYP11B1 (0.59) | CYP11B1CYP11B2GRM2IL4I1NPC1 | |
| SCHEMBL5759646 | 0.72 | TAS2R14 (0.41) | CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| CN-101208328-B | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | SANOFI AVENTIS | 2012-02-29 | — | — | CN | disclosed |
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | disclosed |
| CN-101208328-A | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-06-25 | — | — | CN | disclosed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| EP-1741709-A1 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | CYP11B1 30/4885CYP11B2 51/4885GRM2 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.